Kernaussagen
Epidemiologie
Risikofaktoren und Früherkennung
Therapie
-
Die potenziell kurativen Therapieoptionen mit guter Prognose - wie chirurgische
Resektion, Lebertransplantation und lokal ablative Therapie wie RFTA, PEI
und TACE - stehen für den überwiegenden Teil der Patienten, bei denen die
Erkrankung erst in einem fortgeschrittenen Stadium diagnostiziert wird, nicht
mehr zur Verfügung.
-
Unter einem palliativen Aspekt kann bei nicht zu großem Tumor, fehlenden Hinweisen
für eine Gefäßinvasion sowie guter Leberfunktion die TACE lebensverlängernd
wirken.
-
Darüber hinaus gibt es für Patienten mit lokal fortgeschrittenem, multifokalem
oder metastasiertem HCC trotz zahlreicher Studien zur systemischen Chemotherapie,
Hormontherapie und Immunmodulation bisher keine etablierte Therapie mit gesicherter
Wirksamkeit.
-
Eine besondere Herausforderung und Hoffnung liegt deshalb in der weiteren
Erforschung der molekularen Pathogenese und entsprechender zielgerichteter
Therapien, um auch Patienten in fortgeschrittenen Tumorstadien eine effiziente
und verträgliche Behandlungsoption bieten zu können.
-
Grundsätzlich sollten Patienten mit HCC in allen Stadien wegen der Komplexität
der oft interdisziplinären Therapieentscheidungen in Zentren vorgestellt und
möglichst in Studien behandelt werden.
Literatur
- 1
Bosch F X, Ribes J, Diaz M. et al .
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology.
2004;
127
5-16
- 2
Fattovich G, Giustina G, Degos F. et al .
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up
study of 384 patients.
Gastroenterology.
1997;
112
463-472
- 3
Benvegnù L, Gios M, Boccato S. et al .
Natural history of compensated viral cirrhosis: a prospective study on the incidence
and hierarchy of major complications.
Gut.
2004;
53
744-749
- 4
Davila J A, Morgan R O, Shaib Y. et al .
Hepatitis C infection and the increasing incidence of hepatocellular carcinoma:
a population-based study.
Gastroenterology.
2004;
127
1372-1380
- 5
Donato F, Bofetta P, Puoti M.
A meta-analysis of epidemiological studies on the combined effect of hepatitis
B and C virus infections in causing hepatocellular carcinoma.
Int J Cancer.
1998;
75
347-354
- 6
Fattovich G, Stroffolini T, Zagni I. et al .
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Gastroenterology.
2004;
127 (Suppl. 1)
35-50
- 7
Morgan T R, Mandayam S, Jamal M M.
Alcohol and hepatocellular carcinoma.
Gastroenterology.
2004;
127
87-96
- 8
Yuan J M, Govindarajan S, Arakawa K. et al .
Synergism of alcohol, diabetes and viral hepatitis on risk of hepatocellular
carcinoma in US blacks and whites.
Cancer.
2004;
101
1009-1017
- 9
Grando-Lemaire V, Guettier C, Chevret S. et al .
Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors
and histopathology of the non-tumorous liver. Groupe d’Etude et de traitement
du carcinome hepatocellulaire.
J Hepatol.
1999;
31
508-513
- 10
El-Serag H B, Tran T, Everhart J E.
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.
Gastroenterology.
2004;
126
460-468
- 11
Neuschwander-Tetri B A, Caldwell S H.
Nonalcoholic steatohepatitis: summary of a AASLD single topic conference.
Hepatology.
2003;
37
1202-1219
- 12
Marrero J A, Fontana R J, Fu S. et al .
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular
carcinoma.
J Hepatology.
2005;
42
218-224
- 13
Falize L, Guillygomarc’h A, Perrin M. et al .
Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study
of 36 cases.
Hepatology.
2006;
44
472-477
- 14
Ming L, Thorgeirsson S S, Gail M H. et al .
Dominant role of hepatitis B virus ans cofactor role of aflatoxin in hepatocarcinogenesis
in Quidong, China.
Hepatology.
2002;
36
1214-1220
- 15
Bréchot C.
Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and
new paradigms.
Gastroenterology.
2004;
127 (Suppl. 1)
S56-S61
- 16
Liang T J, Heller T.
Pathogenesis of hepatitis C-associated hepatocellular carcinoma.
Gastroenterology.
2004;
127 (Suppl. 1)
S62-S71
- 17
Wu T.
Cyclooxygenase-2 in hepatocellular carcinoma.
Cancer Treat Rev.
2006;
32
28-44
- 18
El-Serag H B.
Hepatocellular carcinoma: recent trends in the United States.
Gastroenterology.
2004;
127
27-34
- 19
Zhang B H, Yang B H, Tang Z Y. et al .
Randomized controlled trial of screening for hepatocellular carcinoma.
J Cancer Res Clin Oncol.
2004;
130
417-422
- 20
Sangiovanni A, Del Ninno E, Fasani P. et al .
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected
during surveillance.
Gastroenterology.
2004;
126
1005-1014
- 21
Spangenberg H C, Thimme R, Blum H E.
Serum markers of hepatocellular carcinoma.
Semin Liver Dis.
2006;
26
385-390
- 22
Bruix J, Sherman M, Llovet J M. et al .
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000
EASL conference. European Association for the Study of the Liver.
J Hepatol.
2001;
35
421-430
- 23
Bolondi L, Gaiani S, Celli N. et al .
Characterisation of small nodules in cirrhosis by assessment of hypervascularity.
Hepatology.
2005;
42
27-34
- 24
Caturelli E, Solmi L, Anti M. et al .
Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating
liver cirrhosis: a multicentre study.
Gut.
2004;
53
1356-1362
- 25
Llovet J M, Chen Y, Wurmbach E. et al .
A molecular signature to discriminate dysplastic nodules from early hepatocellular
carcinoma in HCV cirrhosis.
Gastroenterology.
2006;
131
1758-1767
- 26
Ishii H, Okada S, Okusaka T. et al .
Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol
injection.
Cancer.
1998;
82
1638-1642
- 27
Villa E, Colantoni A, Camma C. et al .
Estrogen receptor classification for hepatocellular carcinoma: comparison with
clinical staging systems.
J Clin Oncol.
2003;
21
441-446
- 28
Okuda K, Ohtsuki T, Obata H. et al .
Natural history of hepatocellular carcinoma and prognosis in relation to treatment.
Study of 850 patients.
Cancer.
1985;
56
918-928
- 29
Gallo . et al .
A new prognostic system for hepatocellular carcinoma: a retrospective study
of 435 patients.
Hepatology.
1998;
28
751-755
- 30
Marrero J A, Fontana R J, Barrat A. et al .
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an
American cohort.
Hepatology.
2005;
41
707-716
- 31
Bruix J, Llovet J M.
Prognostic prediction and treatment strategy in hepatocellular carcinoma.
Hepatology.
2002;
35
519-524
- 32
Mazzaferro V, Regalia E, Doci R. et al .
Liver transplantation for the treatment of small hepatocellular carcinoma in
patients with cirrhosis.
N Engl J Med.
1996;
334
693-699
- 33
Onaca N, Davis G L, Goldstein R M. et al .
Expanded criteria for liver transplantation in patients with hepatocellular
carcinoma: a report from the International Registry of Hepatic Tumors in Liver
Transplantation.
Liver Transpl.
2007;
13
391-399
- 34
Cillo U, Vitale A, Grigoletto F. et al .
Intention-to-treat analysis of liver transplantation in selected, aggressively
treated HCC patients exceeding the Milan criteria.
Am J Transplant.
2007;
7
972-981
- 35
Lu D SK, Yu N C, Raman S S. et al .
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge
to liver transplantation.
Hepatology.
2005;
41
1130-1137
- 36
Porrett P M, Petermann H, Rosen M. et al .
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular
cancer in the current MELD era.
Liver Transpl.
2006;
12
665-673
- 37
Millonig G, Graziadei I W, Freund M C. et al .
Response to preoperative chemoembolization correlates with outcome after liver
transplantation in patients with hepatocellular carcinoma.
Liver Transpl.
2007;
13
272-279
- 38
Otto G, Heise M, Moench C. et al .
Transarterial chemoembolization before liver transplantation in 60 patients
with hepatocellular carcinoma.
Transplant Proc.
2007;
39
537-539
- 39
Trotter J F, Adam R, Lo C M, Kenison J.
Documented deaths of hepatic lobe donors for living donor liver transplantation.
Liver Transpl.
2006;
12
1485-1488
- 40
Knetemann N M, Oberholzer J, Al Saghier M. et al .
Sirolimus-based immunosuppression for liver transplantation in the presence
of extended criteria for hepatocellular carcinoma.
Liver Transpl.
2004;
10
1301-1311
- 41
Bismuth H, Fecteau A.
Kombinationstherapie in der Onkologie - das hepatocelluläre Carcinom.
Chirurg.
1998;
69
360-365
- 42
Strey C W, Zapletal C, Bechstein W O.
Chirurgische Therapie des hepatozellulären Karzinoms.
Gastroenterologe.
2007;
2
20-26
- 43
Muto Y, Moriwaki H, Ninomiya M. et al .
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid,
in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.
N Engl J Med.
1996;
334
1561-1567
- 44
Lau W Y, Leung T W, Ho S K. et al .
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular
carcinoma: a prospective randomised trial.
Lancet.
1999;
353
797-801
- 45
Mazzaferro V, Romito R, Schiavo M. et al .
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after
liver resection in HCV cirrhosis.
Hepatology.
2006;
44
1543-1554
- 46
Chen M S, Li J Q, Zheng Y. et al .
A prospective randomized trial comparing percutaneous local ablative therapy
and partial hepatectomy for small hepatocellular carcinoma.
Ann Surg.
2006;
243
321-328
- 47
Huang G T, Lee P H, Tsang Y M. et al .
Percutaneous ethanol injection versus surgical resection for the treatment of
small hepatocellular carcinoma: a prospective study.
Ann Surg.
2005;
242
36-42
- 48
Lencioni R A, Allgaier H P, Cioni D. et al .
Small hepatocellular carcinoma in cirrhosis: randomised comparison of radio-frequency
thermal ablation versus percutaneous ethanol injection.
Radiology.
2003;
228
235-240
- 49
Shiina S, Teratani S, Obi S. et al .
A randomized controlled trial of radiofrequency ablation with ethanol injection
for small hepatocellular carcinoma.
Gastroenterology.
2005;
129
122-130
- 50
Llovet J M, Bruix J.
Systematic review of randomized trials for unresectable hepatocellular carcinoma:
chemoembolization improves survival.
Hepatology.
2003;
37
429-442
- 51
Llovet J M, Real M I, Montana X. et al .
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients
with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet.
2002;
359
1734-1739
- 52
Cammà C, Schepis F, Orlando A. et al .
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis
of randomized controlled trials.
Radiology.
2002;
224
47-54
- 53
Patt Y Z, Hassan M M, Lozano R D. et al .
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant
interferon alfa-2b for treatment of hepatocellular carcinoma.
J Clin Oncol.
2003;
21
421-427
- 54
Nowak A K, Stockler M R, Chow P K. et al .
Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.
Cancer.
2005;
103
1408-1414
- 55
Chow P K, Tai B C, Tan C K. et al .
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:
A multicenter randomized controlled trial.
Hepatology.
2002;
36
1221-1226
- 56
Groupe d’Etude et de Traitement de Carcinome Hepatocellulaire .
Randomized trial of leuprorelin and flutamide in male patients with hepatocellular
carcinoma treated with tamoxifen.
Hepatology.
2004;
40
1361-1369
- 57
Villa E, Ferretti I, Grottola A. et al .
Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized
by variant oestrogen receptors.
Br J Cancer.
2001;
84
881-885
- 58
Yuen M F, Poon R T, Lai C L. et al .
A randomized placebo-controlled study of long-acting octreotide for the treatment
of advanced hepatocellular carcinoma.
Hepatology.
2002;
36
687-691
- 59
Becker G, Allgaier H P, Olschewski M. et al .
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized
controlled double-blind study.
Hepatology.
2007;
45
9-15
- 60
Takayama T, Sekine T, Makuuchi M. et al .
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular
carcinoma: a randomised trial.
Lancet.
2000;
356
802-807
- 61
Llovet J M, Sala M, Castells L. et al .
Randomized controlled trial of interferon treatment for advanced hepatocellular
carcinoma.
Hepatology.
2000;
31
54-58
- 62
Kawata S, Yamasaki E, Nagase T. et al .
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.
A randomized controlled trial.
Br J Cancer.
2001;
84
886-891
Prof. Dr. med. Wolfgang E. Fleig
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Straße 27
04103 Leipzig
Email: wolfgang.fleig@uniklinik-leipzig.de
